Why do one person’s ADHD symptoms differ from another’s? The answer lurks inside the structural and chemical differences of the ADHD brain.
No single brain region is the source of ADHD. However, subtle variations in brain structure, function, connectivity, and neurochemistry shape the neural networks that govern attention, motivation, reward, emotion, and self-control.
The regions involved in ADHD traits include:
- The prefrontal cortex (PFC): Research has shown that this brain region, which helps manage attention, planning, decision making, emotional control, and other executive functions, develops more slowly in ADHD brains.1 It is also slightly smaller than in neurotypical brains.
- The amygdala, accumbens, caudate, putamen, and hippocampus are involved in reward, emotion, habit formation, memory, and motivation. These brain regions tend to be smaller in people with ADHD.2, 3 This could contribute to difficulty staying motivated for low-interest tasks, stronger emotional reactions, and challenges shifting attention.
- The frontal and cingulate regions, which help with planning, decision-making, error monitoring, and self-control, are also smaller in ADHD than in neurotypical brains.4, 5 These differences may help explain why people with ADHD often know what they should do but struggle to consistently do it.
[Get This Free Download: Unraveling the Mysteries of Your ADHD Brain]
The Signal-to-Noise Glitch
The brain comprises billions of nerve cells called neurons. These neurons work in circuits, passing signals to each other that allow our bodies to think, move, remember, manage emotions, and control impulses.
Between neurons is a tiny gap called a synapse. To get messages across, neurons release chemical messengers called neurotransmitters into the gap. The neurotransmitters cross the gap and attach to receptors on the next neuron to help the message continue. Afterward, the brain clears neurotransmitters away in a process called reuptake.
The neurotransmitters dopamine (DE) and norepinephrine (NE) help the PFC hold goals and instructions in mind, filter distractions, and guide behavior. They also help reward circuits decide what feels interesting, urgent, or worth doing.
In ADHD, these signals don’t support those circuits and processes as strongly or consistently as they should. Task-relevant information may fade too quickly, while distractions, impulses, emotions or immediate rewards may pull more strongly. This is why ADHD is sometimes described as a “signal-to-noise” problem: the useful signal is there, but it may be drowned out by competing noise.
Charting Brain Networks
ADHD is linked to differences in how brain networks communicate and coordinate attention, motivation, emotion, and self-regulation.
| ADHD Brain Connectivity Findings |
Implications |
The “task manager” network is too tightly connected to the systems involved with mind-wandering and emotions, but not strongly connected to networks that help us shift attention.
The frontoparietal network helps with planning, working memory, problem-solving, and goal-directed behavior. In ADHD, this network shows stronger connectivity with the default mode and affective networks, and weaker connectivity with the ventral attention network.6 |
Turning intention into action is difficult when the task manager network is pulled by internal thoughts or emotions. |
The default mode network (DMN) tends to remain active.
The DMN is typically active during daydreaming and inward thought. During focused work, the DMN is supposed to quiet down, but doesn’t always do so in the ADHD brain.7, 8 |
The ADHD brain may struggle to shift into the right mode to focus and turn down mental noise. |
Reward and motivation circuitry assign value differently.
Reward-related circuits help the brain decide what feels interesting or worth doing. Studies suggest that ADHD brains are relatively less activated or motivated by promised future rewards.9, 10 |
Immediate rewards are typically favored over future rewards. |
How ADHD Medications Work
ADHD medication can optimize brain signals by slowing the reuptake of DE or NE, increasing their release, or activating receptors that strengthen signaling. All of this helps guide attention, motivation, and self-control.
COMPARING THE IMPACTS OF ADHD MEDICATIONS
| Stronger & Longer Signal |
| The gold standard for ADHD treatment, stimulant medication, increases the availability of dopamine (DE) and norepinephrine (NE) so that signals persist long enough to strengthen communication in those networks.
New insights: Functional connectivity data show that stimulants enhance performance by increasing vigilance and perceived task value.11 In other words, stimulants help the ADHD brain stay motivated and engaged with non-preferred tasks. |
METHYLPHENIDATE
- Targets DE and NE transporters
- Blocks reuptake of both, causing them to remain in the synaptic space for longer
|
AMPHETAMINE
- Dual mode of action; inhibits reuptake and increases release of DE and NE
- Tends to have higher efficacy on symptoms but more side effects
|
| Longer Signal |
Higher Specificity Signal |
ATOMOXETINE (Strattera)
- Blocks NE reuptake, raising its levels
- No large DE spikes mean less reinforcement and abuse potential
|
ALPHA-2A AGONISTS
(Guanfacine & Clonidine) Alpha-2A receptors are a specific kind of receiver for NE. Guanfacine and clonidine (Onyda XR) work by turning on these receptors, which helps the PFC hold onto signals that support attention, working memory, and self-control.
- Can be more effective when combined with a stimulant
- These medications also reduce arousal in the nervous system, which is why they can help with insomnia and emotional impulsivity
|
VILOXAZINE (Qelbree)
- Blocks NE reuptake
- Also modulates serotonin signaling, which can help emotional impulsivity, frustration, and other mood symptoms
|
Serotonin Spotlight
In addition to dopamine and norepinephrine, a third critical neurotransmitter is serotonin, which helps to regulate mood and emotion, both deeply relevant to the ADHD experience.
Emotional dysregulation is a core feature of ADHD, and many people with the condition also live with mood disorders. Almost half of adults with ADHD are also prescribed selective serotonin reuptake inhibitors (SSRIs) – medications that increase serotonin levels to regulate mood, emotion, and sleep.
Viloxazine, a non-stimulant, became the first ADHD medication in the U.S. to also modulate serotonin. Beyond targeting ADHD symptoms, the medication was shown to improve co-occurring depression and anxiety in adults with all three conditions.12
Centanafadine (Simtriyo), a stimulant ADHD medication recently approved for children aged 6 years and older and adults, is a norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). Trials show that the medication improves symptoms in both groups and in adults with ADHD and co-occurring anxiety.13
ADHD Brain Boosters
Untreated ADHD impacts neural connectivity.14 Unstable brain connections increase risk for the development of anxiety, depression, insomnia, emotional frustration, and other challenges. ADHD medication enhances neural connectivity, but there are other ways to promote neural growth, protect the brain, and decrease risk for secondary issues.
- Consistent exercise, especially aerobic activity, stimulates the release of neurotransmitters15
- Quality sleep clears metabolic waste from the brain16
- Mental stimulation encourages the creation of new neural pathways
- Positive experiences, like social connection, activate systems that support resilience.17, 18
The ADHD Brain: Next Steps
Greg W. Mattingly, M.D., is an associate clinical professor at Washington University School of Medicine.
ADDITUDE IS HUMAN
Artificial intelligence does not create or edit any written content published by ADDitude. Our editorial team is 100% human, and our mission is simple: listen to and serve our readers with hand-crafted, expert-informed resources. To support ADDitude, please consider subscribing. Your readership and support help make our commitment possible. Thank you.
Sources
1 Shaw, P., Eckstrand, K., Sharp, W., Blumenthal, J., Lerch, J. P., Greenstein, D., Clasen, L., Evans, A., Giedd, J., & Rapoport, J. L. (2007). Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proceedings of the National Academy of Sciences of the United States of America, 104(49), 19649–19654. https://doi.org/10.1073/pnas.0707741104
2Hoogman, M., Bralten, J., Hibar, D., Mennes, M., Zwiers, M., Schweren, L., Hulzen, K. V., Medland, S., Shumskaya, E., Jahanshad, N., Zeeuw, P., Székely, E., Sudre, G., Wolfers, T., Onnink, A., Dammers, J. T., Mostert, J., Vives-Gilabert, Y., Kohls, G., . . . Fisher, J. (2017). Subcortical brain volume differences of participants with ADHD across the lifespan: an ENIGMA collaboration. The lancet. Psychiatry, 4, 310 – 319. https://doi.org/10.1016/s2215-0366(17)30049-4
3 Bralten, J., Greven, C., Franke, B., Mennes, M., Zwiers, M., Rommelse, N., Hartman, C., Van Der Meer, D., O’Dwyer, L., Oosterlaan, J., Hoekstra, P., Heslenfeld, D., Arias-Vásquez, A., & Buitelaar, J. (2016). Voxel-based morphometry analysis reveals frontal brain differences in participants with ADHD and their unaffected siblings.. Journal of psychiatry & neuroscience : JPN, 41 4, 272-9 . https://doi.org/10.1503/jpn.140377
4 Ekhlasi, A., Nasrabadi, A., & Mohammadi, M. (2021). Direction of information flow between brain regions in ADHD and healthy children based on EEG by using directed phase transfer entropy. Cognitive Neurodynamics, 15, 975 – 986. https://doi.org/10.1007/s11571-021-09680-3
5 Yu, M., Gao, X., Niu, X., Zhang, M., Yang, Z., Han, S., Cheng, J., & Zhang, Y. (2023). Meta-analysis of structural and functional alterations of brain in patients with attention-deficit/hyperactivity disorder. Frontiers in Psychiatry, 13. https://doi.org/10.3389/fpsyt.2022.1070142
6 Gao, Y., Shuai, D., Bu, X., Hu, X., Tang, S., Zhang, L., … Huang, X. (2019). Impairments of large-scale functional networks in attention-deficit/hyperactivity disorder: a meta-analysis of resting-state functional connectivity. Psychological Medicine, 49(15), 2475–2485. doi:10.1017/S003329171900237X
7 Norman, L., Sudre, G., Price, J., Shastri, G. G., & Shaw, P. (2022). Evidence from “big data” for the default-mode hypothesis of ADHD: a mega-analysis of multiple large samples. Neuropsychopharmacology, 48, 281-289. https://doi.org/10.1038/s41386-022-01408-z
8 Duffy, K., Rosch, K., Nebel, M. B., Seymour, K., Lindquist, M., Pekar, J., Mostofsky, S., J., & Cohen, R. (2021). Icreased Integration Between Default Mode and Task-Relevant Networks in Children with ADHD is Associated with Impaired Response Control.
9 Plichta, M. M., & Scheres, A. (2014). Ventral-striatal responsiveness during reward anticipation in ADHD and its relation to trait impulsivity in the healthy population: a meta-analytic review of the fMRI literature. Neuroscience and biobehavioral reviews, 38, 125–134. https://doi.org/10.1016/j.neubiorev.2013.07.012
10 Jackson, J. N., & MacKillop, J. (2016). Attention-Deficit/Hyperactivity Disorder and Monetary Delay Discounting: A Meta-Analysis of Case-Control Studies. Biological psychiatry. Cognitive neuroscience and neuroimaging, 1(4), 316–325. https://doi.org/10.1016/j.bpsc.2016.01.007
11 Kay, B. P., Wheelock, M. D., Siegel, J. S., Raut, R. V., Chauvin, R. J., Metoki, A., Rajesh, A., Eck, A., Pollaro, J., Wang, A., Suljic, V., Adeyemo, B., Baden, N. J., Scheidter, K. M., Monk, J. S., Whiting, F. I., Ramirez-Perez, N., Krimmel, S. R., Shinohara, R. T., Tervo-Clemmens, B., … Dosenbach, N. U. F. (2025). Stimulant medications affect arousal and reward, not attention networks. Cell, 188(26), 7529–7546.e20. https://doi.org/10.1016/j.cell.2025.11.039
12 Adler LA, Lieberman VR, Brijbasi L, et al. Viloxazine extended release in adults with attention-deficit/hyperactivity disorder and depression and/or anxiety symptoms: results from a decentralized, open-label, phase 4 trial. J Clin Psychiatry. 2026; 2026;87(2):25m16234.
13 https://www.otsuka-us.com/news/otsuka-announces-positive-phase-3b-results-centanafadine-adults-adhd-and-comorbid-anxiety
14 Ohnishi, T., Toda, W., Itagaki, S., Sato, A., Matsumoto, J., Ito, H., Ishii, S., Miura, I., & Yabe, H. (2023). Disrupted structural connectivity and less efficient network system in patients with the treatment-naive adult attention-deficit/hyperactivity disorder. Frontiers in psychiatry, 14, 1093522. https://doi.org/10.3389/fpsyt.2023.1093522
15 Revelo Herrera, S. G., & Leon-Rojas, J. E. (2024). The Effect of Aerobic Exercise in Neuroplasticity, Learning, and Cognition: A Systematic Review. Cureus, 16(2), e54021. https://doi.org/10.7759/cureus.54021
16 Reddy, O. C., & van der Werf, Y. D. (2020). The Sleeping Brain: Harnessing the Power of the Glymphatic System through Lifestyle Choices. Brain sciences, 10(11), 868. https://doi.org/10.3390/brainsci10110868
17 Eisenberger, N., & Cole, S. (2012). Social neuroscience and health: neurophysiological mechanisms linking social ties with physical health. Nature Neuroscience, 15, 669-674. https://doi.org/10.1038/nn.3086
18 Dutcher, J. M., & Creswell, D. (2018). The role of brain reward pathways in stress resilience and health. Neuroscience and Biobehavioral Reviews, 95, 559–567. https://doi.org/10.1016/j.neubiorev.2018.10.014